Table 1. Pharmacologically controlled in... | American Society of Hematology

Table 1.

Pharmacologically controlled in vivo selection reported in large-animal models and patients

Selection strategy	Selectable gene	Selectable agent	Species	Selection	Source
CID	F36v-mpl	AP20187	Dog	2/2 dogs, transient	Neff et al⁵¹
CID	G-CSF receptor	Estrogen, tamoxifen	Cynomolgus monkey	3/6 monkeys, transient	Hanazono et al⁵⁶
Drug resistance	DHFR	NBMPR-P + trimetrexate	Rhesus macaque	6/6 macaques, transient	Persons et al¹³
Drug resistance	MDR1	Paclitaxel	Dog	1/3 dogs, transient (based on PCR analysis)	Licht et al¹⁴
				2/3 monkeys, very moderate selection, duration
Drug resistance	MDR1	Paclitaxel	Marmoset	not analyzed	Hibino et al⁵²
Drug resistance	MDR1	Paclitaxel	Human	3/6 patients, durability not studied	Moscow et al⁵³
Drug resistance	MDR1	Etoposide	Human	4/4 evaluable patients, transient	Abonour et al⁵⁴
Drug resistance	MGMT	O⁶BG and carmustine	Dog	2/2 dogs, durable	Neff et al¹²
Drug resistance	MGMT	O⁶BG and temozolomide	Dog	2/2 dogs, durable	Neff et al⁵⁵

Selection strategy	Selectable gene	Selectable agent	Species	Selection	Source
CID	F36v-mpl	AP20187	Dog	2/2 dogs, transient	Neff et al⁵¹
CID	G-CSF receptor	Estrogen, tamoxifen	Cynomolgus monkey	3/6 monkeys, transient	Hanazono et al⁵⁶
Drug resistance	DHFR	NBMPR-P + trimetrexate	Rhesus macaque	6/6 macaques, transient	Persons et al¹³
Drug resistance	MDR1	Paclitaxel	Dog	1/3 dogs, transient (based on PCR analysis)	Licht et al¹⁴
				2/3 monkeys, very moderate selection, duration
Drug resistance	MDR1	Paclitaxel	Marmoset	not analyzed	Hibino et al⁵²
Drug resistance	MDR1	Paclitaxel	Human	3/6 patients, durability not studied	Moscow et al⁵³
Drug resistance	MDR1	Etoposide	Human	4/4 evaluable patients, transient	Abonour et al⁵⁴
Drug resistance	MGMT	O⁶BG and carmustine	Dog	2/2 dogs, durable	Neff et al¹²
Drug resistance	MGMT	O⁶BG and temozolomide	Dog	2/2 dogs, durable	Neff et al⁵⁵